LYRA
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
P/B of -0.25 indicates the company's liabilities exceed its assets.
- Negative Price/Book ratio
- No Graham Number available
- No earnings to support P/E valuation
Growth metrics are in a state of total collapse.
- Revenue growth of -96.70%
- Q/Q revenue growth of -96.65%
- No clear path to profitability
Historical price performance is a total wipeout.
- Some recent EPS beats
- 5-year price change of -99.9%
- Consistent history of massive quarterly losses
Piotroski score of 1/9 is a definitive signal of financial weakness.
- Current ratio > 1.0
- Piotroski F-Score 1/9
- Negative ROE of -6594.98%
- Negative ROA of -36.06%
Dividend strength is 0/100.
- No dividend history
- Zero payout capacity
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for LYRA and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
LYRA
Lyra Therapeutics, Inc.
Primary
|
-99.9% | -99.5% | -87.8% | -91.8% | -50.8% | +32.6% |
|
AKAN
Akanda Corp.
Peer
|
-100.0% | -100.0% | -96.4% | -95.4% | -13.6% | -6.7% |
|
BDRX
Biodexa Pharmaceuticals Plc
Peer
|
-100.0% | -100.0% | -95.1% | -75.6% | -24.0% | -4.0% |
|
ADTX
Aditxt, Inc.
Peer
|
-100.0% | -100.0% | -100.0% | -99.8% | -67.1% | -51.2% |
|
IMCC
IM Cannabis Corp.
Peer
|
-99.9% | -91.4% | -72.7% | -81.3% | -57.0% | +6.5% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
LYRA
Lyra Therapeutics, Inc.
|
BEARISH | $1.15M | - | -6595.0% | -% | $0.65 | |
|
AKAN
Akanda Corp.
|
BEARISH | $1.73M | 0.01 | -60.9% | -266.3% | $0.82 | Compare |
|
BDRX
Biodexa Pharmaceuticals Plc
|
BEARISH | $1.8M | - | -61.8% | -% | $2.15 | Compare |
|
ADTX
Aditxt, Inc.
|
BEARISH | $0.4M | - | -% | -% | $1.82 | Compare |
|
IMCC
IM Cannabis Corp.
|
BEARISH | $2.25M | - | -% | -20.7% | $0.36 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-06 | PALASIS MARIA | Chief Executive Officer | Sale | 1,702 | $5,726 |
| 2026-01-06 | CAVALIER JASON | Chief Financial Officer | Sale | 769 | $2,587 |
| 2025-11-13 | PERCEPTIVE ADVISORS LLC | Beneficial Owner of more than 10% of a Class of Security | Sale | 45,875 | $182,515 |
| 2025-11-10 | PERCEPTIVE ADVISORS LLC | Beneficial Owner of more than 10% of a Class of Security | Sale | 70,390 | $344,219 |
Past News Coverage
Recent headlines mentioning LYRA from our newsroom.